Core Insights - Annovis Bio Inc. is participating in the 13th Alzheimer's & Parkinson's Drug Development Summit to discuss advancements in treatments for neurodegenerative diseases [1][2] - The company emphasizes the need for a holistic approach to treatment, addressing multiple neurotoxic proteins rather than focusing on a single target [2] Company Overview - Annovis Bio is a late-stage clinical drug platform company based in Malvern, Pennsylvania, dedicated to developing therapies for Alzheimer's disease (AD) and Parkinson's disease (PD) [1][3] - The company aims to improve patient outcomes and quality of life through innovative therapies [3] Event Participation - Annovis will present data from Phase III clinical trials of its drug Buntanetap and participate in a panel discussion on March 19, focusing on new therapeutic approaches for Parkinson's disease [2] - The summit is recognized as a comprehensive industry-focused meeting that covers the entire spectrum of neurodegenerative disease research and development [2]
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment